Brind.
  1. The FDA approved Korlym for Cushing's syndrome on July 6, 2025.

A trial was conducted on July 4, 2025, testing the product Korlym for diabetes.

1 report, 0 independent Updated Jul 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

A trial was conducted on July 4, 2025, testing the product Korlym for diabetes.

Who's involved

What this event is mainly about
Corcept Therapeutics

Keep exploring

Part of

The FDA approved Korlym for Cushing's syndrome on July 6, 2025. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • Unknown outlet